Outcomes in small children on Berlin Heart EXCOR support: age and body surface area as clinical predictive factors

Sofie Rohde1, Eugen Sandica2, Kevin Veen1

  • 1Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands.

Insights

The Berlin Heart EXCOR (BHE) is effective for pediatric patients, with high recovery rates in the smallest children (BSA <0.53 m2). Age and body surface area (BSA) do not predict mortality in BHE-supported patients.

Area of Science:

  • Pediatric Cardiology
  • Mechanical Circulatory Support
  • Medical Device Outcomes

Background:

  • The Berlin Heart EXCOR (BHE) provides circulatory support for pediatric patients.
  • Outcomes and care requirements for BHE support vary significantly across different pediatric age groups.
  • Understanding age- and size-related outcomes is crucial for optimizing BHE therapy.

Purpose of the Study:

  • To analyze age- and body surface area (BSA)-related outcomes in pediatric patients receiving Berlin Heart EXCOR (BHE) support.
  • To identify factors influencing mortality, transplant rates, and recovery in this patient cohort.
  • To evaluate the efficacy of BHE across diverse pediatric age and size categories.

Main Methods:

  • Utilized data from the EUROMACS database for patients <19 years old supported by BHE between 2000 and 2021.
  • Employed maximally selected rank statistics to determine critical body surface area (BSA) cut-off values.
  • Conducted multivariable Cox proportional hazard regression with ridge penalization to identify outcome predictors.

Main Results:

  • A total of 303 patients were analyzed (mean age: 2.0 years).
  • Mortality was not significantly associated with age or BSA (P > 0.67).
  • Higher transplant rates were linked to older age (HR 1.07, P=0.006) and non-congenital heart disease etiology (HR 1.46, P=0.020).
  • Recovery rates were highest in patients with BSA <0.53 m2 (21.8% at 1 year).
  • Patients with BSA ≥0.73 m2 showed lower early pump thrombosis risk but higher early bleeding risk compared to those with BSA <0.73 m2.

Conclusions:

  • Patient age and BSA do not predict mortality in Berlin Heart EXCOR support.
  • The BHE demonstrates remarkably high recovery rates in the smallest pediatric patients (BSA <0.53 m2).
  • The BHE is a viable and effective therapeutic option for even the youngest and smallest pediatric patients requiring circulatory support.
Abstract